To our knowledge, this is a novel mechanism of developing resistance to sunitinib in a certain population of ccRCC, and these results indicate that IL13RA2 could be one of potential target to overcome sunitinib resistance. This evidence concerns the gene IL13RA2 and nonpapillary renal cell carcinoma.